Core Viewpoint - The recent issuance of the "Several Measures to Support the High-Quality Development of Innovative Drugs" by the National Medical Insurance Administration and the National Health Commission is expected to provide significant support for the innovative drug industry, leading to a new wave of benefits for the sector [1][4]. Group 1: Commercial Health Insurance - The new measures include the establishment of a commercial health insurance innovative drug directory, which will focus on innovative drugs with high clinical value and significant patient benefits that exceed basic medical insurance coverage [2][3]. - The commercial health insurance sector is experiencing rapid growth, with original premium income projected to reach 977.3 billion yuan in 2024, marking an 8.2% year-on-year increase [3]. - The measures aim to clarify the boundaries of basic medical insurance coverage, allowing commercial health insurance to expand its development space [3]. Group 2: Investment and Funding - The measures encourage commercial health insurance companies to invest in innovative drug research and development through various means, including innovative drug investment funds, to foster "patient capital" [4]. - There is an expectation that these initiatives will provide more "active water" for the innovative drug industry and create pathways for monetization [4]. Group 3: Drug Access and Data Utilization - The measures promote the expedited entry of innovative drugs into designated medical institutions and encourage timely adjustments to drug supplies based on clinical needs [5][6]. - The total sales of drugs across three major terminals (hospitals, pharmacies, and others) are projected to reach 1.94 trillion yuan in 2024, with public hospitals remaining the primary sales channel [5]. - The measures also highlight the importance of utilizing medical insurance data to support innovative drug research, with plans to develop data products that align with the needs of drug development [6].